NDLI: Neurotrophic factors in neurodegenerative disorders: Model of parkinson’s disease

Content Provider	Springer Nature Link
Author	Yebenes, Justo Garcia Mena, Maria Angeles
Copyright Year	2000
Abstract	Neurotrophic factors are compounds that enhance neuronal survival and differentiation. Most of these compounds exert their pharmacological actions on selective types of neurons, and therefore, are considered promising new therapeutic agents for the treatment of different neurodegenerative disorders characterized by selective degeneration of certain neuronal groups. Those compounds have been used in humans for several neurological disorders including amyotrophic lateral sclerosis — ciliary derived neurotrophic factor (CNTF) and brain derived neurotrophic factor (BDNF), Alzheimer’s disease and peripheral neuropathy — nerve growth factor (NGF) and Parkinson’s disease (PD) — glial derived neurotrophic factor (GDNF).In spite of well founded clinical experiments by previous experimental work in animal models some of these trials have been negative. For instance, animal models of PD have shown that several neurotrophic factors, including GDNF and other compounds, reduce apoptosis and increase resistance of dopamine neurons to neurotoxinsin vitro. These compounds prevent or recover the damage to dopamine neurons of rodents and primates produced by chemical or mechanical acute lesions including 6-OHDA, MPTP, methamphetamine and axotomy.The differences between the promising results obtained in experimental models and the lack of clinical results or excessive toxicity found in humans could be attributed to the following reasons: (a) Lack of relevance between the pathogenesis of the experimental lesion and the corresponding neurodegenerative disorder. (b) Poor correlation between results obtained in acute, self-limited, selective deficit produced to experimental animals and those available in more complex, chronic and progressive disorders involving patients. (c) Inadequate delivery of the active product to the target area in the human brain. (d) Poor information from acute experiments in animals which does not predict long-term effects of chronic infusion in humans. Further experimental work, therefore, is needed to transfer these neurotrophic factors to the clinic.
Starting Page	115
Ending Page	137
Page Count	23
File Format	PDF
ISSN	10298428
Journal	Neurotoxicity Research
Volume Number	2
Issue Number	2-3
e-ISSN	14763524
Language	English
Publisher	Springer-Verlag
Publisher Date	2000-01-01
Publisher Place	New York
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	FGF GDNF IGF-I Neurotrophins TGF Growth factors receptors Neurodegeneration Neuroprotection Parkinson’s disease Neurosciences Pharmaceutical Sciences/Technology Neurology Neurochemistry Pharmacology/Toxicology Neurobiology
Content Type	Text
Resource Type	Article
Subject	Neuroscience Toxicology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Neurotrophic factors for the investigation and treatment of movement disorders

Neuroprotection in Parkinson’s disease; a commentary

The putative neuroprotective role of dopamine agonists in parkinson’s disease

Estrogen and brain vulnerability

Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases

Neuroprotective effects of nicotine against salsolinol-induced cytotoxicity: Implications for parkinson’s disease

PACAP Protects Against Inflammatory-Mediated Toxicity in Dopaminergic SH-SY5Y Cells: Implication for Parkinson’s Disease

Neuroprotective strategies for HIV-1 associated dementia

Prospects for redox-based therapy in neurodegenerative diseases

Neurotrophic factors in neurodegenerative disorders: Model of parkinson’s disease

Similar Documents

Neurotrophic factors for the investigation and treatment of movement disorders

Neuroprotection in Parkinson’s disease; a commentary

The putative neuroprotective role of dopamine agonists in parkinson’s disease

Estrogen and brain vulnerability

Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases

Neuroprotective effects of nicotine against salsolinol-induced cytotoxicity: Implications for parkinson’s disease

PACAP Protects Against Inflammatory-Mediated Toxicity in Dopaminergic SH-SY5Y Cells: Implication for Parkinson’s Disease

Neuroprotective strategies for HIV-1 associated dementia

Prospects for redox-based therapy in neurodegenerative diseases

Neurotrophic factors in neurodegenerative disorders: Model of parkinson’s disease